MannKind (MNKD) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 24% YoY to $101.9M; commercial product revenue increased to $45.0M, with Furoscix adoption and Afrezza pediatric demand supporting growth.

• Nine-month revenue increased 27% to $301.4M; the five-year revenue CAGR was 42%.

• Growth spans commercial products, United Therapeutics royalties and manufacturing, and DPI pipeline programs targeting lung diseases.

Financial highlights

• Q3 GAAP net loss was $23.224M versus net income of $7.985M a year earlier; adjusted net loss was $3.615M versus adjusted net income of $22.447M.

• Nine-month GAAP net loss was $58.874M versus net income of $21.811M; adjusted net loss was $10.408M versus adjusted net income of $57.977M.

• Q3 commercial product sales were $45.0M versus $22.3M; royalties were $37.5M, up 12%, and collaborations and services were $19.4M, down 27%.

• Nine-month commercial product revenue rose 90% to $120.9M; royalties rose 8% to $102.6M, and collaboration revenue was $180.5M.

Outlook and guidance

• Q4 GAAP and non-GAAP profitability is expected, with record revenue; annual profitability is expected in 2027, though not necessarily in Q1.

• Furoscix Q4 revenue is expected to exceed H1 2026 revenue; ReadyFlow adoption is expected to inform future dosage-form mix and margins.

• Estimated cumulative collaboration revenue for 2027–2030 exceeds $1B, based on current assumptions and not intended as financial guidance.

• A $15M ralinepag DPI milestone is anticipated in 2027; nintedanib DPI Phase 2 data are expected in H1 2028.